XTX Topco Ltd Makes New $61,000 Investment in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

XTX Topco Ltd bought a new position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 61,515 shares of the company’s stock, valued at approximately $61,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Lineage Cell Therapeutics during the first quarter worth approximately $30,000. Rhumbline Advisers boosted its holdings in shares of Lineage Cell Therapeutics by 15.1% during the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after purchasing an additional 17,411 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock worth $239,000 after purchasing an additional 70,418 shares during the period. Comerica Bank boosted its holdings in shares of Lineage Cell Therapeutics by 84,745.8% during the first quarter. Comerica Bank now owns 250,295 shares of the company’s stock worth $370,000 after purchasing an additional 250,000 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Lineage Cell Therapeutics by 35.7% during the second quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock worth $435,000 after purchasing an additional 114,762 shares during the period. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Craig Hallum assumed coverage on shares of Lineage Cell Therapeutics in a report on Tuesday, August 20th. They set a “buy” rating and a $4.00 price target for the company.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX opened at $0.92 on Thursday. The company has a market cap of $174.15 million, a P/E ratio of -6.59 and a beta of 1.26. Lineage Cell Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $1.28 million. Lineage Cell Therapeutics had a negative net margin of 391.00% and a negative return on equity of 36.30%. Analysts predict that Lineage Cell Therapeutics, Inc. will post -0.12 earnings per share for the current year.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.